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Through a series of synthetic model peptides, we have examined the structural requirements of the P, and PX residues in statine-based HIV protease 
(PR) inhibitors. Results agree with the general observations that, the more bulky the P, aromatic hydrophobic side’chain, the more potent is the 
inhibitor. At P,, an isopropyl side chain is critical in maintaining potency. Three-dimensional modeling demonstrates that the steric bulk of a leucyl 
residue or the unfavorable energy transfer, from water to enzyme, for a basic amino acid residue at P, markedly compromises activity. A 
naphthylalaninyl-valyl P,-P, substituted analogue inhibits PR with an ICso value of 6 nM, and was also effective as an antiviral agent. 
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1. INTRODUCTION 
To date, reverse-transcriptase (RT) inhibitors (e.g. 
AZT) are the only antiviral agents available for treating 
AIDS (acquired immunodeficiency syndrome), a dis- 
ease that remains to be lethal. An alternative target for 
rational antiviral agent design is the virally encoded 
aspartyl proteinase (PR) which has been shown to be 
essential for the posttranslational processing of viral 
Pr55@g and Pr160gag-P“’ polyproteins of the pathogenic 
HIV Recent reports suggest that the PR also plays a 
role in promoting the cellular mechanism of transcrib- 
ing viral DNA [l] and in the early pre-integration phase 
of the replication cycle of HIV [2]. In addition, the 
cytopathic effect of HIV might be related to the pro- 
teinase’s ability to specifically cleave non-viral sub- 
strates as observed in vitro [3,4]. Therefore, PR inhibi- 
tion might provide very unique opportunities for treat- 
ing AIDS. 
Despite the fact that many synthetic PR inhibitors are 
reported to be highly potent in vitro ([S] and references 
therein), the design of PR inhibitors remains to be a 
challenging topic. We have reported a series of statine 
(or its variants)-containing hexa- to nonapeptides that 
are potent inhibitors against the PR as well as being 
antivirals [6]. We also demonstrated the antiviral effi- 
cacy of one mildly active statine-based protease inhibi- 
tor (SBPI) in an animal model of murine retroviral dis- 
ease [7]. The reported results strongly support our and 
others’ opinion that SBPIs represent an important ap- 
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preach in designing more effective antiviral agents ei- 
ther as potentially useful clinical agents or as pharma- 
cological probes to delineate the mechanism of viral 
infection [8]. Drug resistance has emerged as a serious 
stumblingblock in antiviral therapy. HIV mutates rap- 
idly, and new strains frequently evolve within the pa- 
tient that are able to withstand the medicine, often 
within a few months after the start of the therapy. In 
designing protease inhibitors, incorporating the un- 
usual amino acid statine at the PlPl’ position, because 
of its rather broad activity towards different aspartyl 
proteases, may offer an approach to study and verify 
the hypothesis that a broad-spectrum HIV protease in- 
hibitor would be more effective in controlling HIV 
In the present work, we used the shortened analogue 
of a previously reported SBPI as a template to investi- 
gate systematically the structural requirements of the P3 
and P2 residues in SBPIs. The relative potencies of the 
inhibitors were determined by measuring their IC,, val- 
ues against PR. A computer model of the three-dimen- 
sional structure of HIV-l proteinase and its inhibitors 
at the active site was then used to analyze the structure- 
activity relationships (SAR). The model predicts certain 
interactions between the inhibitors and the Sz and S3 
subsites in the catalytic center of PR and explains some 
of the differences in inhibitory activity. Two active in- 
hibitors were tested for their antiviral activity in a cell 
culture-based assay system. Details of the work are pre- 
sented as follows. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
All commercial protected amino acids were obtained from Ad- 
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vanced ChemTech, Inc. (Louisville, KY) and 2-quinolinecarboxylic 
acid was from Aldrich Chemical Co. (Milwaukee, WI). The side-chain 
protecting groups were tosyl for histidine and arginine, benzyl for 
tyrosine, and 2-chlorobenzyloxycarbonyl for lysine. w-Boc-p- 
(Fmoc)aminophenylalanine [9] and Boc-L-3(1’-naphthyl)alanine [lo] 
were prepared as described. The synthetic peptides were prepared in 
a stepwise manner ontop-methylbenzhydrylamine resin using a stand- 
ard manual solid-phase peptide synthesis method. For peptidyl resins 
carrying a Fmoc-para-aminophenylalanine’residue, the removal of the 
Fmoc group was carried out as the last step by treating the peptidyl 
resin with 30% piperidine in DMF twice, for an hour each time. After 
HF cleavage, the peptides were purified by preparative HPLC, charac- 
terized by amino acid analysis and fast atom bombardment mass 
spectrometry. 
2.2. Assays 
In vitro PR inhibitory activities of the synthetic analogues were 
evaluated by an assay system consisting of site-specific proteolysis, at 
pH 5.5, of a fluorescent synthetic substrate by a recombinant HIV-l 
proteinase we reported previously [q. The antiviral potency assay was 
performed using human T-lymphoblastoid CEM and MT2 cells as 
reported [6]. 
2.3. Molecular modeling 
The crystal structure of HIV-l protease has been resolved independ- 
ently by different laboratories [1 l-131. In the present molecular mod- 
eling work, we have adopted the coordinates of the three-dimensional 
structure of HIV-l protease reported by Wlodawer et al. [12] obtained 
from the Brookhaven Protein Databank. The molecular modeling 
method involved the minimization of the interaction energy between 
a statine-containing peptide inhibitor and the enzyme dimer. Energy 
calculations were performed using the AMBER 3.0 program. Initially, 
we utilized the atomic model of inhibitor MVT-101 and its orientation 
in the enzyme-inhibitor complex reported by Miller et al. [15] in posi- 
tioning a statine residue in the catalytic site of HIV-1 protease. In 
doing so, a statine residue was docked in the catalytic site in a manner 
in which its backbone and isobutyl side chain superimposed with the 
backbone and the P, side chain of MVT-101. This orientation of 
statine resulted in close proximity between the residue’s hydroxyl 
group and the catalytic Asp residues. All residues in the enzyme that 
were 8.0 A away from the statine residue were held fixed. The rest of 
the enzyme molecule, including the active site water molecule, but not 
the Asp-25 and Asp-124 residues (the AMBER software numbered the 
enzyme dimer as if it were a single-chain polypeptide. Asp-124 would 
be Asp-25’ in a dimeric-enzyme numbering system), were allowed to 
move. The united atom option was invoked for the enzyme but an all 
atom inhibitor was used. The Asp-25 was modeled as the acid (pro- 
tonated) residue and the Asp-124 was modeled as a base. After this 
preliminary model was constructed, the complex structure was refined 
by using the AMBER energy refinement program. With the statine 
residue assuming an optimal final position, other residues of the inhib- 
itory peptide were incorporated as a /?-sheet backbone. This prelimi- 
nary enzyme complex was constructed in a manner that maximizes the 
hydrogen bonds between the peptidyl backbone of the inhibitor and 
the enzyme, and maximizes the hydrophobic interactions of the amino 
acid side chains, while minimizing any unfavorable steric interaction. 
Energy refinement was performed once again as usual. In the resulting 
model, the B-sheet conformation of the statine-containing inhibitors 
was preserved, in a manner similar to those of MVT-101 [15] and 
pepstatine [33]. The differences between our inhibitors and either one 
of the two known structures, pepstatin and MVT-101, is the significant 
area of concern. These differences are embodied in the fact that there 
are different side chains attached to the p-sheet backbone. The result- 
ing minimized structure for one active inhibitor can serve as a starting 
position for another inhibitor, by changing the appropriate side 
chains. The graphics representation was achieved with the program 
INSIGHT and displayed on an Evans and Sutherland PS390. 
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3. RESULTS AND DISCUSSION 
HIV-l proteinase, a member of the aspartyl protease 
family, is known to hydrolyze a number of substrates 
each at a different rate. Therefore, the proteinase, even 
though it appears to be rather specific in regard to the 
scissile bonds that it cleaves, accommodates equences 
of various structures [16,17]. These observations sug- 
gest that, unlike renin which is highly substrate specific, 
the catalytic subsites of PR can accommodate ligands 
that are quite different in structure. One may also trans- 
late, teleologically, these observations into more oppor- 
tunities in designing potent PR inhibitors. An approach 
in rational inhibitor design starts with creating SAR 
data on subsite specificity of proteinase catalytic site 
ligands. A number of detailed studies on PR substrate 
subsite analysis have been reported [ 1 S-211 and the data 
generated has been effectively applied to reduced-bond 
inhibitor design [22]. 
While substrate subsite specificity studies have led to 
general conclucions on certain chemical preference at 
different subsites within a series of synthetic ligands, 
such SAR may not always extrapolate to inhibitor bind- 
ing. Since subsite specificity of PR may also be strongly 
influenced by the sequence of the substrate 
[16,21,23,24], it becomes apparent hat a systematic sub- 
site specificity search on catalytic site inhibitors would 
generate more relevant SAR data in designing antiviral 
agents. In designing PR inhibitors, the incorporation of 
a hydroxyl-containing transition-state residue in place 
of the P,-P,, scissile-bond ipeptide has been proven to 
be a very effective approach in producing potent inhib- 
itors ([5] and references therein). In analogy to the pro- 
teinase’s ubstrates, the affinity of each series of transi- 
tion-state inhibitors is remarkably influenced by the 
structures of the side chains at the Pa, P3, P,, and P,, 
Table 1 
Optimal structure at the P, position 
Code Sequence 1% (nM) 
p, p, P, P,. P,, P3, 
A Ac-Phe-Val-Statine-Leu-Phe-NH, 90 
B Ac-paF-Val-Statine-Leu-Phe-NH, 80 
C Ac-YOM-Val-Statine-Leu-Phe-NH, 16 
D Ac-Tyr-Val-Statine-Leu-Phe-NH, 43 
E Ac-Trp-Val-Statme-Leu-Phe-NH, 13 
F Ac-Pro-Val-Statine-Leu-Phe-NH, 1,062 
G Ac-Nal-Val-Statine-Leu-PheNH, 6 
H QC-Val-Statine-Leu-Phe-NH, 3,650 
statine, (3&4S)-4-amino-3-hydroxy-6-methylheptanoic acid; Nal, 3- 
(I’-naphthyl)alanine; YOM, O-methyltyrosine; paF, p-aminophenyla- 
lanine; QC, quinoline-2-carbonyl. The synthetic peptides were charac- 
terized by amino acid analysis and fast atom bombardment mass 
spectrometry. HIV proteinase inhibition was assayed as outlined in 
section 2. Each IC,, value is the average result of three experiments. 
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Fig. 1. Stereoscopic computer model of inhibitor A Ac-Phe-Val-Statine-Leeu-Phe-NH2 (orange color) in the HIV-l active site. Amino acid residues 
of the proteinase shown are within 8 A away from the P2 position in the inhibitor. The catalytic aspartate side chains (numbered 25 and 124) and 
the statyl-OH group are in red color. The Ile-84 side chain of the S, hydrophobic pocket is in green. 
Fig. 2. Stereoscopic omputer model of inhibitor I Ac-Phe-Leu-Statine-Leu-Phe-NH, (orange color) in the HIV-l active site. The model shows 
the occurrence of steric hindrance between the PJ..eu side chain and that of Ile-84. See legend to Fig. 1 for other description. 
Fig. 3. Stereoscopic omputer model of inhibitor L Ac-Nal-His-Statine-Leu-Phe-NH, (orange color) in the HIV-l active site. The side chains of 
Ile-84, Val-32 and Ile-47 of the S2 hydrophobic pocket surrounding the P,-histidyl imidazole group are in green. See legend to Fig. 1 for other 
description. 
positions [25-271. Therefore, knowledge of the interac- 
tion of each of these positions to their corresponding 
enzyme subsites would help in designing optimal inhib- 
itors. Thus the mode of binding of the P, or Pi, subsite 
of a series of hydroxyethylene isostere protease inhib- 
itors was delineated recently through in vitro enzyme 
inhibition studies and in combination with X-ray crys- 
tallography [30-321. 
We reported previously a series of potent seven to 
nine amino acids statine-containing proteinase inhib- 
itors [6]. Based on X-ray crystallography evidence that 
the PR ligand binding cleft extends from S3 to S3’ sub- 
sites [15,31], a series of SBPIs spanning from P3 to P,,, 
with systematic replacement of either the P2 or P3 amino 
acid residue, were synthesized in attempt to arrive at 
principles that could be used to design potent SBPIs. 
Crystallographic analysis of complexes between HIV 
PR and active-site inhibitors revealed that the S3 subsite 
binds the inhibitor’s P3 side chains through hydropho- 
bic interactions [l&32,33]. Billich et al. studied the effect 
of variations of P3 structures on the relative cleavage 
efficiency of a series of synthetic substrates [16]. They 
reported that aromatic residues, especially Phe and Tyr 
are preferred over aliphatic (except methionine) resi- 
dues. In our study, a series of analogues containing 
aromatic ring structures were synthesized in order to 
examine the optimal structure. The cc-amino termini 
were acetylated since it was shown that acetyl-pep- 
statine is significantly more potent than isovaleryl-pep- 
statine [34] probably due to difference in the solvation 
effect of the capping structures [33]. 
Table I summarizes our results on the optimal struc- 
ture at the P, position in binding to the enzyme. The 
aromatic amino acids tested and their relative affinity 
towards the proteinase were 1’-naphthylalanine >tryp- 
tophan > o-methyltyrosine > tyrosine > p-aminophen- 
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ylalanine > phenylalanine. The most potent inhibitor 
was G which exhibited an anti-proteinase IC,o value of 
6 nM. It appears that the more bulky the aromatic side 
chain, the more potent the inhibitor is. Our study agrees 
with those of Prasad et al. who reported the best inhibi- 
tion activity occurred when either Y-naphthylalanine or 
m- biphenylalanine was incorporated at the P3 position 
of a series of hydroxyethylamine-containing substrate 
inhibitors [35]. In another report describing molecular 
modeling of a potent dihydroxyethylene(DHE)-con- 
taining inhibitor (1-naphthoxyacetyl-His-DHE-Ile- 
AMP) complexed with HIV-l protease, the naphthoxy 
group is part of a terminal group which allows a large 
degree of flexibility. The naphthyl ring is not buried in 
the enzyme model and is lying partially outside the ac- 
tive site with no specific orientation but apparently in- 
teracting non-specifically with a number of large hydro- 
phobic regions on the enzyme surface [36]. In contrast, 
molecular modeling of compound A (Fig. 1) and G (not 
shown), when docked in the active cleft of PR, demon- 
strates, in the case of the statine-containing inhibitors, 
that both the phenyl and naphthyl rings are buried 
within the enzyme. They are stacked parallel to the 
Asp-Arg ion pair in the enzyme, and against the Val of 
the inhibitor in position P,. Since the inhibitor back- 
bone maintains a /?-sheet conformation it limits the po- 
sition and orientation of the a-methylene unit (corre- 
sponding to the ether oxygen of the naphthoxy group 
above). These restraints force the naphthyl group in the 
statine-containing inhibitors into the position shown in 
Fig. 3. In addition, the conformation of this naphthyl 
group is fixed and cannot rotate 180 degrees to be more 
exposed to solvent, since to do so would result in a steric 
interaction between the methylene group at the naph- 
thylene-l-position and the hydrogen at the naph- 
thylene-8- position (peri interaction). 
In agreement with a substrate subsite specificity study 
[16], Pro at P3 was not well tolerated in our inhibitor. 
Compound F having a Pro at P3 was three orders of 
magnitude less potent than its naphthylalanyl analogue 
G. Through a systematic SAR search, Roberts et al. 
discovered a quinoline-2-carbonyl (QC) moiety at P3 is 
a highly preferred structure in designing potent pro- 
teinase inhibitors that contain an (R)-hydroxyethylam- 
ine P,P,, replacement [25]. However, in contrast to what 
had been observed, the substitution at P, with a QC 
group in statine-containing inhibitors did not produce 
a potent inhibitor. Compund H was mildly active 
(IC,, = 3.65 ,uM) when compared with other P,-aro- 
matic members of the series. 
We previously reported that for statine-containing 
octapeptide inhibitors, PR discriminates remarkably 
between a valine and a histidine at the P2 position. The 
virus-specific proteinase accommodated inhibitors with 
valine at P, but apparently rejected the histidyl ana- 
logues. In the present study, we further characterized 
the structural requirements of the P2 residue in a series 
of pentapeptides. Table II lists the potency values of the 
peptides substituted at P, position with aliphatic, polar 
(neutral), and basic residues. Although it is believed, 
like the S3 subsite, that the S2 subsite of PR is hydropho- 
bic in nature, limited crystallographic detail is available 
in analysing the interaction between the subsite and its 
ligand side chain structure. However, empirical replace- 
ments of the PZ residue have been based on hydrophobic 
(e.g. [31]) and polar characteristics (e.g. [25]) of the sub- 
stituting residue in comparison to those occurring in the 
natural substrates [16]. In the present series of statine- 
containing peptides, there is a dramatic difference in 
preference of valine over leucine at P, even though both 
residues are hydrophobic aliphatic homologues. Chang- 
ing from an isopropyl to an isobutyl side chain resulted 
essentially in an inactive peptide (A vs. I). This result 
shows a stringent steric requirement at the enzyme S2 
pocket. It was reported that synthetic chromogenic sub- 
strates consisting of B-branched residues, Val or Ile, at 
the P, position were hydrolyzed by PR at a faster rate 
than that of a Leu-containing analogue [19]. The polar 
amino acid Asn occurs repeatedly as a P2 residue in a 
number of known substrates for HIV PR. This observa- 
tion led to a popular approach of incorporating Asn 
immediately adjacent o the amino side of a transition- 
state P,P,, replacement when designing potent pro- 
teinase inhibitors (see [5]). However, in the statine-con- 
taining series (Table II) Asn, as well as Gln, remarkably 
lowered potency. Both Asn- or Gln-substituted peptides 
(K and J) were three orders of magnitude less potent 
than the valyl analogue (G). A similar result was ob- 
served by Richards et al. in three pseudo-palindromic 
sequences ubstituted by an aromatic variant of statine 
at PiPi, carrying an Asn or Gin at the P, position, the 
peptides were either weak inhibitors or inactive [17]. 
In our experience with statine-containing analogues 
that span from P,, to P5 or P,, a histidine at P2 produced 
ineffective PR inhibitors [6]. In contrast to our observa- 
tion, a highly potent hydroxyethylene-containing pro- 
teinase inhibitor that spans from P,. to P3 with a histid- 
ine at the P2 position has been reported [36]. We 
extended our study to the effect of other basic amino 
Code 
Table II 
Comparison of Pz structuresA 
Sequence 
A 
1 
G 
J 
K 
L 
M 
N 
Ac-Phe-Val-Statine-Leu-Phe-NH, 90 
Ac-Phe-Leu-Statine-Leu-Phe-NH, - 10,000 
AC-Nal-Val-Statine-Leu-Phe-NH, 6 
Ac-Nal-Gln-Statine-Leu-Phe-NH, 3,300 
Ac-Nal-Asn-Statine-Leu-Phe-NH, 4,600 
Ac-Nal-His-Statine-Leu-Phe-NH, 7,200 
AC-Nal-Lys-Statine-Leu-Phe-NH, na 
Ac-Nal-Arg-Statine-Leu-Phe-NH, na 
Go MM) 
“See footnote to Table I. The symbol na indicates no significant 
inhibitory activity detected at 10 ,uM. 
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acids (lysine and arginine) at the P, position (Table II). 
In vitro inhibition assay (pH 5.5) results show that ana- 
logues (M and N) carrying these residues were devoid 
of activity when tested up to 10 PM concentration. Our 
observation is consistent with a substrate-hydrolysis 
study, in which a Lys at the P2 position prevented cleav- 
age of a synthetic substrate [21]. The histidyl analogue 
L retained a weak inhibitory activity probably because 
the aromatic imidazole group partially compensated the 
loss of activity caused by a positively charged side chain. 
From an examination of our three-dimensional 
model, it is apparent hat an isopropyl side chain of the 
P2 residue of an inhibitor fits well in the Sz pocket 
without causing steric hindrance. Fig. 1 shows that in 
A, the P,-valine side chain is surrounded by the en- 
zyme’s amino residues Ala-28 Val-32, Ile-47, Ile-84 and 
Ile-149 which make up the S, hydrophobic pocket. 
Whereas. when the free-energy minimized A was con- 
verted to I (by replacing valine with leucine residue), an 
obvious steric hindrance of the isobutyl side chain with 
Ile-84 is then easily seen (Fig. 2). While there are several 
low energy P,-Leu side chain conformations in addition 
to the one shown here, all interfere sterically in some 
way. Although minimizing the energy reduces some of 
the unfavorable steric interactions, new strains are cre- 
ated in other regions of the complex. For minimal steric 
interaction, the distance between the united-atom car- 
bon of Ile-84 and a substrate hydrogen should be 
greater than the sum of the van der Waals radii which 
is 3.0 A. The results of the calculations for the P,-histi- 
dine containing compound L are shown in Fig. 3. Our 
starting conformation for L is based on a model for G 
(not shown) in which the phenyl ring in the P,-position 
of A is replaced by a naphthalene ring. This was further 
altered to produce a model for L by minimizing the two 
different torsion angles for the histidine alpha-beta 
bond. Figs. 1 and 3 show that the pocket around the Val 
in A or the one around the His in L is essentially hydro- 
phobic. The later pocket is delineated by the hydropho- 
bic side chains of residues Val-32, Ala-28, Ile-84, Ile-149 
and Ile-47 (compare with Fig. 1). It appears that the 
very weak activity of L is due to the energetically unfa- 
vorable transfer of the hydrophilic histidine from an 
aqueous environment o the hydrophobic environment 
Table III 
Antiviral effects of synthetic HIV proteinase inhibitors 
Compound CEM MT-2 
of the enzyme. No hydrogen bonds can be made to the 
histidine side chain without desolvating it, an energeti- 
cally unfavorable process. In the case of L, the histidine 
residue does not interfere sterically but does not have 
an opportunity, either, to make effectively hydrogen 
bonds in the hydrophobic environment. Desolvation of 
the histidine residue is then an important factor that 
reduces activity. In the cases where Pz is a charged 
residue (as for Lys and Arg in M and N, respectively), 
desolvation and steric hindrance would be expected to 
play a role in deteriorating the potency. 
Since compounds G and A were shown to inhibit the 
enzymatic function of PR (G being most potent and the 
other moderately active), we also tested their antiviral 
activity against HIV-l in CEM and MT-2 cells [6]. 
Assay results (Table III), indeed, show these com- 
pounds were effective antiviral agents although their 
antiviral potency was lower than those usually reported 
for AZT (3’-azido-2’,3’-dideoxythymidine) or ddC 
(2’,3’-dideoxycytidine) [6] which are RT inhibitors. 
Considering factors like antiviral potency and peptidyl 
nature, it is unlikely that either G or A is a desirable 
clinical agent for the treatment of AIDS. Nevertheless, 
these two compounds might be economical experimen- 
tal tools useful in delineating certain antiviral pharma- 
cological principles. Additional modifications at the P, 
and PY positions may further enhance potency [37,38]. 
Very recently, a combined regimen of more than one 
RT inhibitor has been shown to elicit synergistic in vitro 
antiviral effect. Wouldn’t it be even more beneficial in 
antagonizing HIV by means of a dual inhibitory strat- 
egy acting on both PR and RT? 
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